Stocks / BSX
BSX stock forecast
BOSTON SCIENTIFIC CORP · Healthcare · Medical Devices
Where this rating comes from: The Upfront Model, whose picks have been recorded with a fingerprint the day they publish since September 18, 2026. See the record.
BSX is not among the 20 largest holdings published for 2026 Q4. See the portfolio
BSX against the S&P 500
| Period | BSX | S&P 500 (SPY) |
|---|---|---|
| 1 month | -3.1% | -4.7% |
| 3 months | -16.1% | -4.8% |
| Year to date | -54.2% | +7.9% |
| 1 year | -56.0% | +11.8% |
Total return, dividends included.
Key numbers
| Price | $43.64 |
| Market cap | 63.26 Billion |
| P/E (trailing 12 months) | 18.3 |
| P/S (trailing 12 months) | 3.0 |
| P/B (latest quarter) | 2.5 |
| Gross margin | 69.1% |
| Net profit margin | 16.6% |
| Return on equity | 13.9% |
| Beta | 0.3 |
As of November 2, 2026.
BSX and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| EW | EDWARDS LIFESCIENCES CORP | 60.51 Billion | Underperform | BSX vs EW |
| DXCM | DEXCOM INC | 30.78 Billion | Outperform | BSX vs DXCM |
| STE | STERIS PLC | 25.21 Billion | Greatly Underperform | BSX vs STE |
| ZBH | ZIMMER BIOMET HOLDINGS INC | 19.55 Billion | Underperform | |
| ALGN | ALIGN TECHNOLOGY INC | 11.56 Billion | Outperform | |
| PODD | INSULET CORP | 9.71 Billion | Outperform |
Questions
What does the Upfront Investment model say about BSX?
The model rates BOSTON SCIENTIFIC CORP (BSX) "Greatly Outperform" as of November 18, 2026, which means its medium-term return forecast is in the top fifth of the stocks the model scores. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the BSX rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is BSX in the Upfront Investment model portfolio?
BSX is not among the 20 largest holdings published for 2026 Q4.
The rating is generated by The Upfront Model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.